These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 30872378)

  • 1. δ-Catenin Promotes Bevacizumab-Induced Glioma Invasion.
    Shimizu T; Ishida J; Kurozumi K; Ichikawa T; Otani Y; Oka T; Tomita Y; Hattori Y; Uneda A; Matsumoto Y; Date I
    Mol Cancer Ther; 2019 Apr; 18(4):812-822. PubMed ID: 30872378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glioma cell VEGFR-2 confers resistance to chemotherapeutic and antiangiogenic treatments in PTEN-deficient glioblastoma.
    Kessler T; Sahm F; Blaes J; Osswald M; Rübmann P; Milford D; Urban S; Jestaedt L; Heiland S; Bendszus M; Hertenstein A; Pfenning PN; Ruiz de Almodóvar C; Wick A; Winkler F; von Deimling A; Platten M; Wick W; Weiler M
    Oncotarget; 2015 Oct; 6(31):31050-68. PubMed ID: 25682871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibroblast growth factor 13 regulates glioma cell invasion and is important for bevacizumab-induced glioma invasion.
    Otani Y; Ichikawa T; Kurozumi K; Inoue S; Ishida J; Oka T; Shimizu T; Tomita Y; Hattori Y; Uneda A; Matsumoto Y; Michiue H; Date I
    Oncogene; 2018 Feb; 37(6):777-786. PubMed ID: 29059154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined targeting of interleukin-6 and vascular endothelial growth factor potently inhibits glioma growth and invasiveness.
    Saidi A; Hagedorn M; Allain N; Verpelli C; Sala C; Bello L; Bikfalvi A; Javerzat S
    Int J Cancer; 2009 Sep; 125(5):1054-64. PubMed ID: 19431143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of convection-enhanced delivery of bevacizumab on survival of glioma-bearing animals.
    Wang W; Sivakumar W; Torres S; Jhaveri N; Vaikari VP; Gong A; Howard A; Golden EB; Louie SG; Schönthal AH; Hofman FM; Chen TC
    Neurosurg Focus; 2015 Mar; 38(3):E8. PubMed ID: 25727230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SOX15 exerts antitumor function in glioma by inhibiting cell proliferation and invasion via downregulation of Wnt/β-catenin signaling.
    Zhang D; Guo S; Wang H; Hu Y
    Life Sci; 2020 Aug; 255():117792. PubMed ID: 32416168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
    Bota DA; Alexandru D; Keir ST; Bigner D; Vredenburgh J; Friedman HS
    J Neurosurg; 2013 Dec; 119(6):1415-23. PubMed ID: 24093630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncolytic Herpes Virus Armed with Vasculostatin in Combination with Bevacizumab Abrogates Glioma Invasion via the CCN1 and AKT Signaling Pathways.
    Tomita Y; Kurozumi K; Yoo JY; Fujii K; Ichikawa T; Matsumoto Y; Uneda A; Hattori Y; Shimizu T; Otani Y; Oka T; Kaur B; Date I
    Mol Cancer Ther; 2019 Aug; 18(8):1418-1429. PubMed ID: 31092561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumstatin attenuates the promotion effect of IL-17 secreted by Th17 cells on the stemness maintenance of glioma cells.
    Yu W; Hu J; Le H; Lu Y; Xu W; Yu W; Shen W
    Pathol Res Pract; 2021 Jul; 223():153463. PubMed ID: 33971545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FAM84B acts as a tumor promoter in human glioma via affecting the Akt/GSK-3β/β-catenin pathway.
    Wang M; Li C; Shi W
    Biofactors; 2021 Jul; 47(4):600-611. PubMed ID: 33759248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of proline-rich tyrosine kinase 2 activation-mediated C6 glioma cell invasion after anti-vascular endothelial growth factor therapy.
    Xu CS; Wang ZF; Dai LM; Chu SH; Gong LL; Yang MH; Li ZQ
    J Transl Med; 2014 May; 12():148. PubMed ID: 24884636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nobiletin inhibits invasion via inhibiting AKT/GSK3β/β-catenin signaling pathway in Slug-expressing glioma cells.
    Zhang X; Zheng K; Li C; Zhao Y; Li H; Liu X; Long Y; Yao J
    Oncol Rep; 2017 May; 37(5):2847-2856. PubMed ID: 28339056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNA-383 expression regulates proliferation, migration, invasion, and apoptosis in human glioma cells.
    Xu D; Ma P; Gao G; Gui Y; Niu X; Jin B
    Tumour Biol; 2015 Sep; 36(10):7743-53. PubMed ID: 25936342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combining bevacizumab with temozolomide increases the antitumor efficacy of temozolomide in a human glioblastoma orthotopic xenograft model.
    Mathieu V; De Nève N; Le Mercier M; Dewelle J; Gaussin JF; Dehoux M; Kiss R; Lefranc F
    Neoplasia; 2008 Dec; 10(12):1383-92. PubMed ID: 19048117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TCTP promotes glioma cell proliferation in vitro and in vivo via enhanced β-catenin/TCF-4 transcription.
    Gu X; Yao L; Ma G; Cui L; Li Y; Liang W; Zhao B; Li K
    Neuro Oncol; 2014 Jan; 16(2):217-27. PubMed ID: 24311645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Downregulation of HIF-1a sensitizes U251 glioma cells to the temozolomide (TMZ) treatment.
    Tang JH; Ma ZX; Huang GH; Xu QF; Xiang Y; Li N; Sidlauskas K; Zhang EE; Lv SQ
    Exp Cell Res; 2016 May; 343(2):148-158. PubMed ID: 27090014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel MET/TIE2/VEGFR2 inhibitor altiratinib inhibits tumor growth and invasiveness in bevacizumab-resistant glioblastoma mouse models.
    Piao Y; Park SY; Henry V; Smith BD; Tiao N; Flynn DL; de Groot JF
    Neuro Oncol; 2016 Sep; 18(9):1230-41. PubMed ID: 26965451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bevacizumab with angiostatin-armed oHSV increases antiangiogenesis and decreases bevacizumab-induced invasion in U87 glioma.
    Zhang W; Fulci G; Buhrman JS; Stemmer-Rachamimov AO; Chen JW; Wojtkiewicz GR; Weissleder R; Rabkin SD; Martuza RL
    Mol Ther; 2012 Jan; 20(1):37-45. PubMed ID: 21915104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD44 expression in the tumor periphery predicts the responsiveness to bevacizumab in the treatment of recurrent glioblastoma.
    Nishikawa M; Inoue A; Ohnishi T; Yano H; Kanemura Y; Kohno S; Ohue S; Ozaki S; Matsumoto S; Suehiro S; Nakamura Y; Shigekawa S; Watanabe H; Kitazawa R; Tanaka J; Kunieda T
    Cancer Med; 2021 Mar; 10(6):2013-2025. PubMed ID: 33543833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of delta-catenin is associated with progression of human astrocytoma.
    Wang M; Dong Q; Zhang D; Wang Y
    BMC Cancer; 2011 Dec; 11():514. PubMed ID: 22151302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.